Malignant meningiomas
- PMID: 32586496
- DOI: 10.1016/B978-0-12-822198-3.00044-6
Malignant meningiomas
Abstract
Malignant meningiomas are WHO Grade III meningiomas representing 1% of all meningiomas. They are comprised of three histologic types: anaplastic, rhabdoid, and papillary. They can arise de novo or as a result of biologic progression of meningiomas of lower histologic grades. The overall survival of patients with WHO grade III meningiomas is 2-3 years. Surgery is the main treatment, while radiotherapy is thought to slow tumor growth. Multiple trials have been attempted on chemotherapeutic agents, hormonal therapies, small molecule and anti-angiogenic agents without robust evidence of efficacy. The rarity of these tumors is the main reason for our patchy understanding of the natural history and lack of effective treatment options. There is an urgent need to develop alternative therapies given the significantly increased risk of complication and co-mordibity associated with repeated surgeries in this population.
Keywords: Anaplastic; Anaplastic meningioma; Malignant; Meningioma; Papillary; Radiotherapy; Rhabdoid; Surgery.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence.Neuropathology. 2010 Jun;30(3):279-87. doi: 10.1111/j.1440-1789.2009.01060.x. Epub 2009 Sep 14. Neuropathology. 2010. PMID: 19780983
-
[Meningiomas: new prognostic factors].An R Acad Nac Med (Madr). 2007;124(2):319-32; discussion 330-2. An R Acad Nac Med (Madr). 2007. PMID: 18069599 Spanish.
-
Atypical meningiomas.Handb Clin Neurol. 2020;170:233-244. doi: 10.1016/B978-0-12-822198-3.00043-4. Handb Clin Neurol. 2020. PMID: 32586495 Review.
-
Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?J Neurooncol. 2018 Apr;137(2):331-336. doi: 10.1007/s11060-017-2721-4. Epub 2017 Dec 21. J Neurooncol. 2018. PMID: 29270884
-
[Problems in treatment for meningiomas].Nihon Rinsho. 2005 Sep;63 Suppl 9:303-9. Nihon Rinsho. 2005. PMID: 16201539 Review. Japanese. No abstract available.
Cited by
-
Case report: Primary intraosseous meningioma: a radiological study of two cases confirmed pathologically.Front Oncol. 2025 Feb 4;15:1502818. doi: 10.3389/fonc.2025.1502818. eCollection 2025. Front Oncol. 2025. PMID: 39968065 Free PMC article.
-
Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3.Cancers (Basel). 2022 Sep 26;14(19):4689. doi: 10.3390/cancers14194689. Cancers (Basel). 2022. PMID: 36230612 Free PMC article. Review.
-
Interdisciplinary Therapeutic Approaches to Atypical and Malignant Meningiomas.Cancers (Basel). 2023 Aug 25;15(17):4251. doi: 10.3390/cancers15174251. Cancers (Basel). 2023. PMID: 37686527 Free PMC article. Review.
-
Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models.World J Exp Med. 2025 Jun 20;15(2):102897. doi: 10.5493/wjem.v15.i2.102897. eCollection 2025 Jun 20. World J Exp Med. 2025. PMID: 40546670 Free PMC article.
-
Metastatic meningioma: a case series and systematic review.Acta Neurochir (Wien). 2023 Oct;165(10):2873-2883. doi: 10.1007/s00701-023-05687-3. Epub 2023 Jul 26. Acta Neurochir (Wien). 2023. PMID: 37491650 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources